Exelixis | EXEL - Equity Capital And Reserves


Exelixis reported $1.94B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Akebia Therapeutics USD 27.38M 5.24M Mar/2026
Amgen USD 9.19B 532M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Bayer EUR 28.85B 2.9B Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Cytokinetics USD -826.57M 166.94M Mar/2026
Eisai JPY 898.99B 9.36B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Exelixis USD 1.94B 225.57M Mar/2026
Genmab DKK 5.85B 96M Dec/2025
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sanofi EUR 73.14B 1.43B Mar/2026
Takeda JPY 7.77T 129.5B Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Xencor USD 515.63M 119.95M Mar/2026